Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

Document › Details

Fluidigm Corporation. (12/11/18). "Press Release: Fluidigm Announces Commencement of Public Offering of Common Stock". South San Francisco, CA.

	Organisation	Fluidigm Corporation (Nasdaq: FLDM)
	Group	Fluidigm (Group)
	Product	mass cytometry
	Product 2	investment banking
	Index term	Fluidigm–SEVERAL: investment, 201812 public offering $63.3m net $59.1m with 8.15m+1.225m shares common stock at $6.75/share
	Person	Lee, Agnes (Fluidigm 201806 VP Investor Relations)

Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering pursuant to Fluidigm’s existing shelf registration statement. In connection with this offering, Fluidigm expects to grant the underwriters a 30-day option to purchase additional shares of common stock. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies, and to fund possible investments in or acquisitions of complementary businesses, products, or technologies.

Piper Jaffray and UBS Investment Bank are acting as joint book-running managers for the offering.

A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on March 8, 2017, amended on April 28, 2017 and declared effective by the SEC on May 2, 2017. The offering will be made only by means of a written prospectus and prospectus supplement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, and by e-mail at prospectus@pjc.com, and from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, 25th floor, New York, NY 10019, or by phone at 888-827-7275 or by email at ol-prospectus-request@ubs.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Contact

Agnes Lee
Vice President, Investor Relations
agnes.lee@fluidigm.com
Phone: 650-416-7423

Record changed: 2018-12-21